摘要目的 对比二代头孢菌素类抗生素与美洛西林钠舒巴坦钠治疗老年社区获得性肺炎(CAP)的临床疗效.方法 选取80例老年社区获得性肺炎患者为研究对象,以随机数表抽取法将其分为对照组与研究组,每组40例,对照组给予二代头孢菌素类抗生素头孢呋辛钠治疗,研究组给予美洛西林钠舒巴坦钠治疗,对两组患者临床疗效,患者临床体征恢复时间和治疗费用进行统计对比.结果 研究组治疗总有效率(95％)高于对照组(90％),但两组比较差异未见统计学意义(P＞0.05);研究组临床体征恢复时间和治疗费用均低于对照组,两组比较差异有统计学意义(P均＜0.05).结论 二代头孢菌素类抗生素与美洛西林钠舒巴坦钠治疗老年CAP均有显著疗效,但使用美洛西林钠舒巴坦钠治疗患者恢复速度更快,且治疗费用更低,值得临床推广.

abstractsObjective To compare the clinical efficacy of second generation of cephalosporins and mezlocillin sodium with sulbactam sodium on the elder community acquired pneumonia (CAP).Methods Eighty cases of the elder community acquired pneumonia (CAP),in accordance with the random number table,were divided into research group (n =40) and control group (n =40).The control group were given the second generation of cephalosporins,namely cefuroxime sodium,and the research group were given mezlocillin sodium and sulbactam sodium.The recovery time,therapy costs were analyzed.Results The total effective rate of research group (95 ％) was much higher than that of the control group(90％),but there was no significant difference between the two groups(P ＞0.05);the recovery time of clinical signs and therapy costs in the research group were both shorter and less than that in the control group,and the differences were significant(P ＜ 0.05).Conclusions The clinical effect of second generation of cephalosporins and the mezlocillin sodium and sulbactam sodium the elder community acquired pneumonia(CAP) is good,but patients treated with mezlocillin sodium and sulbactam sodium recover fast and cost less,which is worth of clinical promotiom.